ArticleInfection2012
Hepatitis delta: on soft paws across Germany.
Article in Infection, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting.Alimentary pharmacology & therapeutics · 2025Article
- Epidemiology Pattern, Prevalent Genotype Distribution, Fighting Stigma and Control Options for Hepatitis D in Bulgaria and Other European Countries.Life (Basel, Switzerland) · 2023Review
- Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008-2012: A cross-sectional study.JHEP reports : innovation in hepatology · 2022Article
- Combination of Novel Therapies for HDV.Viruses · 2022Review
- HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection.Viruses · 2021Article
- Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.Frontiers in public health · 2020Article
- Article
- Anti-HDV seroprevalance among patients with previous HBV infection.Northern clinics of Istanbul · 2018Article
- Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification.Journal of clinical microbiology · 2017Article
- Hepatitis delta virus: A fascinating and neglected pathogen.World journal of virology · 2015Review
- Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study.Journal of clinical microbiology · 2014Article
- Is the HDV seroprevalence in patients admitted to a university hospital representative for all HBV carriers in Germany?Infection · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlobally, more than 350 million people are considered to be chronic carriers of the hepatitis B virus (HBV) infection; thereof, 15-20 million of these individuals are thought to be coinfected with hepatitis delta virus (HDV). The clinical course depends on the mode of transmission; whereas coinfection commonly resolves, superinfection aggravates the disease and progresses to chronicity in over 90 % of the cases, which, again, results in cirrhosis.
objectiveAlthough many tests are performed in HBV carriers, data on the prevalence of anti-HDV-IgG in Germany are only rarely available and outdated. Therefore, we retrospectively evaluated the seroprevalence of anti-HDV-IgG from the results of our routine service. MATERIALS AND
methodsBetween January 2000 and October 2011, serum samples from 2,844 patients (carrying hepatitis B surface antigen) admitted to University Hospital Frankfurt am Main, Frankfurt, Germany, were tested for anti-HDV-IgG by enzyme-linked immunosorbent assay (ELISA).
resultsThe overall seroprevalence of anti-HDV-IgG in the collective of Frankfurt (n = 2,844) is 7.4 % [95 % confidence interval (CI): 6.4-8.4]. The amount of seropositive men (8.3 %, 95 % CI: 6.9-10) significantly exceeds the female proportion (5.7 %, 95 % CI: 4.3-7.5). The rate of seropositivity to anti-HDV-IgG in this collective of Frankfurt reached a maximum in the year 2003 (10.1 %, 95 % CI: 8.9-11.1). The lowest rate was observable in 2004, where 5.4 % were positive to anti-HDV-IgG.
conclusionOf the HBV carriers in Germany, 5-8 % reveal serologic evidence of coinfection with HDV. The vaccination against HBV is the key to prevent HDV infection; therefore, vaccination must strongly be propagated further on.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.